Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1953 1
1954 2
1958 2
1961 1
1962 2
1963 2
1964 2
1965 8
1966 6
1967 5
1968 16
1969 19
1970 19
1971 22
1972 35
1973 37
1974 47
1975 65
1976 59
1977 57
1978 48
1979 55
1980 90
1981 59
1982 82
1983 88
1984 126
1985 118
1986 97
1987 93
1988 109
1989 147
1990 159
1991 162
1992 160
1993 177
1994 201
1995 242
1996 222
1997 285
1998 284
1999 305
2000 311
2001 367
2002 390
2003 420
2004 386
2005 418
2006 497
2007 493
2008 506
2009 545
2010 601
2011 620
2012 682
2013 724
2014 757
2015 699
2016 723
2017 734
2018 785
2019 775
2020 936
2021 1155
2022 1029
2023 932
2024 253

Text availability

Article attribute

Article type

Publication date

Search Results

17,567 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of drug-induced immune thrombocytopenias.
Marini I, Uzun G, Jamal K, Bakchoul T. Marini I, et al. Haematologica. 2022 Jun 1;107(6):1264-1277. doi: 10.3324/haematol.2021.279484. Haematologica. 2022. PMID: 35642486 Free PMC article. Review.
Immune-mediated thrombocytopenia, on the other hand, involves the formation of antibodies that react to platelet-specific glycoprotein complexes, as in classic drug-induced immune thrombocytopenia (DITP), or to platelet factor 4, as in heparin-induced thrombocyto
Immune-mediated thrombocytopenia, on the other hand, involves the formation of antibodies that react to platelet-specific glycoprotei …
Adult Evans' Syndrome.
Michel M. Michel M. Hematol Oncol Clin North Am. 2022 Apr;36(2):381-392. doi: 10.1016/j.hoc.2021.12.004. Epub 2022 Mar 11. Hematol Oncol Clin North Am. 2022. PMID: 35282950 Review.
Evans syndrome (ES) is a rare immune disorder defined as the simultaneous or sequential occurrence in a single patient of immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) autoimmune neutropenia (AIN). ES represents approximately 5% to 10% of all w …
Evans syndrome (ES) is a rare immune disorder defined as the simultaneous or sequential occurrence in a single patient of immune thromboc
Complications of massive transfusion.
Sihler KC, Napolitano LM. Sihler KC, et al. Chest. 2010 Jan;137(1):209-20. doi: 10.1378/chest.09-0252. Chest. 2010. PMID: 20051407 Review.
The lethal triad of acidosis, hypothermia, and coagulopathy associated with MT is associated with a high mortality rate. Other complications include hypothermia, acid/base derangements, electrolyte abnormalities (hypocalcemia, hypomagnesemia, hypokalemia, hyperkalemia), ci …
The lethal triad of acidosis, hypothermia, and coagulopathy associated with MT is associated with a high mortality rate. Other compli …
Randomized Trial of Platelet-Transfusion Thresholds in Neonates.
Curley A, Stanworth SJ, Willoughby K, Fustolo-Gunnink SF, Venkatesh V, Hudson C, Deary A, Hodge R, Hopkins V, Lopez Santamaria B, Mora A, Llewelyn C, D'Amore A, Khan R, Onland W, Lopriore E, Fijnvandraat K, New H, Clarke P, Watts T; PlaNeT2 MATISSE Collaborators. Curley A, et al. N Engl J Med. 2019 Jan 17;380(3):242-251. doi: 10.1056/NEJMoa1807320. Epub 2018 Nov 2. N Engl J Med. 2019. PMID: 30387697 Clinical Trial.
BACKGROUND: Platelet transfusions are commonly used to prevent bleeding in preterm infants with thrombocytopenia. Data are lacking to provide guidance regarding thresholds for prophylactic platelet transfusions in preterm neonates with severe thrombocytopenia. METHO …
BACKGROUND: Platelet transfusions are commonly used to prevent bleeding in preterm infants with thrombocytopenia. Data are lacking to …
Hospital-acquired thrombocytopenia.
McMahon CM, Cuker A. McMahon CM, et al. Hosp Pract (1995). 2014 Oct;42(4):142-52. doi: 10.3810/hp.2014.10.1151. Hosp Pract (1995). 2014. PMID: 25502138 Review.
The development of thrombocytopenia is common in hospitalized patients and is associated with increased mortality. Frequent and important causes of thrombocytopenia in hospitalized patients include etiologies related to the underlying illness for which the pa …
The development of thrombocytopenia is common in hospitalized patients and is associated with increased mortality. Frequent an …
Heparin-induced thrombocytopaenia.
Prince M, Wenham T. Prince M, et al. Postgrad Med J. 2018 Aug;94(1114):453-457. doi: 10.1136/postgradmedj-2018-135702. Epub 2018 Aug 20. Postgrad Med J. 2018. PMID: 30126928 Review.
Heparin-induced thrombocytopaenia (HIT) is a severe and potentially life-threatening adverse drug reaction. Patients become extremely hypercoagulable, and this can lead to life-threatening and limb-threatening thrombosis with a mortality of 5%-10%. HIT is an antibod …
Heparin-induced thrombocytopaenia (HIT) is a severe and potentially life-threatening adverse drug reaction. Patients become extremely …
Heparin-induced thrombocytopenia.
Chong BH. Chong BH. Aust N Z J Med. 1992 Apr;22(2):145-52. doi: 10.1111/j.1445-5994.1992.tb02796.x. Aust N Z J Med. 1992. PMID: 1530537 Review.
Thrombocytopenia is a common adverse effect of heparin therapy. Two types of heparin-induced thrombocytopenia (HIT) are observed clinically--an early onset mild thrombocytopenia (Type I) in which the patients remain asymptomatic and a delayed onset severe
Thrombocytopenia is a common adverse effect of heparin therapy. Two types of heparin-induced thrombocytopenia (HIT) are observ
Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival.
Haddad TC, Zhao S, Li M, Patel SH, Johns A, Grogan M, Lopez G, Miah A, Wei L, Tinoco G, Riesenberg B, Li Z, Meara A, Bertino EM, Kendra K, Otterson G, Presley CJ, Owen DH. Haddad TC, et al. Cancer Immunol Immunother. 2022 May;71(5):1157-1165. doi: 10.1007/s00262-021-03068-2. Epub 2021 Oct 7. Cancer Immunol Immunother. 2022. PMID: 34618180 Free PMC article.
RESULTS: We identified 1,038 patients that met eligibility criteria. Overall, 89 (8.6%) patients developed grade 3 thrombocytopenia; eighteen were attributed to ICI (1.73% overall). Patients who developed grade 3 irTCP had worse overall survival compared to those wh …
RESULTS: We identified 1,038 patients that met eligibility criteria. Overall, 89 (8.6%) patients developed grade 3 thrombocytopenia; …
Managing patients with myelofibrosis and thrombocytopenia.
Yilmaz M, Verstovsek S. Yilmaz M, et al. Expert Rev Hematol. 2022 Mar;15(3):233-241. doi: 10.1080/17474086.2022.2057296. Epub 2022 Mar 29. Expert Rev Hematol. 2022. PMID: 35316110 Review.
INTRODUCTION: Given the progressive nature of myelofibrosis, the incidence of thrombocytopenia increases over time. Furthermore, approved drugs ruxolitinib and fedratinib, induce thrombocytopenia. ...EXPERT OPINION: Up to 25% of patients with myelofibrosis have plat …
INTRODUCTION: Given the progressive nature of myelofibrosis, the incidence of thrombocytopenia increases over time. Furthermore, appr …
Persistent thrombocytopenia predicts poor long-term survival in patients with antiphospholipid syndrome: a 38-year follow-up study.
Pardos-Gea J, Marques-Soares JR, Buján S, Ordi-Ros J, Alijotas-Reig J. Pardos-Gea J, et al. Rheumatology (Oxford). 2022 Mar 2;61(3):1053-1061. doi: 10.1093/rheumatology/keab475. Rheumatology (Oxford). 2022. PMID: 34115832
Thrombocytopenia was defined as <150 109 platelets/l. Hazard ratios (HR) of mortality were calculated using Cox-regression models. ...Persistent low-moderate thrombocytopenia is associated with a reduced long-term survival....
Thrombocytopenia was defined as <150 109 platelets/l. Hazard ratios (HR) of mortality were calculated using Cox-regression
17,567 results
You have reached the last available page of results. Please see the User Guide for more information.